GT BIOPHARMA, INC. Operating Leases, Rent Expense
GT BIOPHARMA, INC. (GTBP) reported Operating Leases, Rent Expense of $50.00 thousand for the 9-month period ending 2020-09-30, per its 10-Q filed 2020-11-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2020-11-13
- GT BIOPHARMA, INC. operating leases, rent expense for the quarter ending 2020-09-30 was $15.00K, a 0.00% change year-over-year.
- GT BIOPHARMA, INC. operating leases, rent expense for the quarter ending 2020-06-30 was $17.80K, a 1.11% decline year-over-year.
- GT BIOPHARMA, INC. operating leases, rent expense for the quarter ending 2020-03-31 was $17.20K, a 1.18% increase year-over-year.
- GT BIOPHARMA, INC. operating leases, rent expense for the quarter ending 2019-12-31 was $19.00K.
- GT BIOPHARMA, INC. operating leases, rent expense for fiscal 2019 was $69.00K, a 666.67% increase from fiscal 2018.
- GT BIOPHARMA, INC. operating leases, rent expense for fiscal 2018 was $9.00K, a 0.00% change from fiscal 2017.
- GT BIOPHARMA, INC. operating leases, rent expense for fiscal 2017 was $9.00K.
- GT BIOPHARMA, INC. operating leases, rent expense for fiscal 2016 was $0.00.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 3 month as first filed | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 6 month as first filed | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 9 month as first filed | Operating Leases, Rent Expense 12 month | Operating Leases, Rent Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-09-30 | $15.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13 | $32.80K derived: sum of 2 quarters · filed 2020-11-13 | $50.00K 10-Q · filed 2020-11-13 | $69.00K derived: sum of 4 quarters · filed 2020-11-13 | ||||
| 2020-06-30 | $17.80K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-18 | $35.00K 10-Q/A · filed 2020-08-18 | $54.00K derived: sum of 3 quarters · filed 2020-08-18 | $69.00K derived: sum of 4 quarters · filed 2020-11-13 | ||||
| 2020-03-31 | $17.20K 10-Q · filed 2020-05-15 | $36.20K derived: sum of 2 quarters · filed 2020-05-15 | $51.20K derived: sum of 3 quarters · filed 2020-11-13 | $69.20K derived: sum of 4 quarters · filed 2020-11-13 | ||||
| 2019-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $34.00K derived: sum of 2 quarters · filed 2020-11-13 | $52.00K derived: sum of 3 quarters · filed 2020-11-13 | $69.00K 10-K · filed 2020-03-27 | ||||
| 2019-09-30 | $15.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2020-11-13 | $33.00K derived: sum of 2 quarters · filed 2020-11-13 | $50.00K 10-Q · filed 2020-11-13 | $52.00M 10-Q · filed 2019-11-14 | -$60.94M derived: sum of 4 quarters · filed 2020-11-13 | |||
| 2019-06-30 | $18.00K derived: 10-Q/A 6 month − 10-Q 3 month · filed 2020-08-18 | $35.00K 10-Q/A · filed 2020-08-18 | $35.00M 10-Q · filed 2019-08-14 | -$60.96M derived: sum of 3 quarters · filed 2020-08-18 | -$53.96M derived: sum of 4 quarters · filed 2020-08-18 | |||
| 2019-03-31 | $17.00K 10-Q · filed 2020-05-15 | -$60.97M derived: sum of 2 quarters · filed 2020-05-15 | -$53.97M derived: sum of 3 quarters · filed 2020-05-15 | $2.00K derived: sum of 4 quarters · filed 2020-05-15 | ||||
| 2018-12-31 | -$60.99M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | -$53.99M derived: sum of 2 quarters · filed 2020-03-27 | -$15.00K derived: sum of 3 quarters · filed 2020-03-27 | $9.00K 10-K · filed 2020-03-27 | $69.00K 10-K · filed 2019-03-29 | |||
| 2018-09-30 | $7.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | $60.98M derived: sum of 2 quarters · filed 2019-11-14 | $61.00M 10-Q · filed 2019-11-14 | $52.00K 10-Q · filed 2018-11-14 | $61.00M derived: sum of 4 quarters · filed 2019-11-14 | |||
| 2018-06-30 | $53.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $54.00M 10-Q · filed 2019-08-14 | $54.00K 10-Q · filed 2018-08-14 | $54.00M derived: sum of 3 quarters · filed 2019-08-14 | $54.00M derived: sum of 4 quarters · filed 2019-08-14 | |||
| 2018-03-31 | $24.00K 10-Q · filed 2019-05-15 | $27.00K 10-Q · filed 2018-05-15 | $24.00K derived: sum of 2 quarters · filed 2019-05-15 | $27.00K derived: sum of 3 quarters · filed 2019-05-15 | $30.00K derived: sum of 4 quarters · filed 2019-05-15 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $3.00K derived: sum of 2 quarters · filed 2019-03-29 | $6.00K derived: sum of 3 quarters · filed 2019-03-29 | $9.00K 10-K · filed 2019-03-29 | ||||
| 2017-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $6.00K derived: sum of 2 quarters · filed 2018-11-14 | $9.00K 10-Q · filed 2018-11-14 | |||||
| 2017-06-30 | $3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $6.00K 10-Q · filed 2018-08-14 | ||||||
| 2017-03-31 | $3.00K 10-Q · filed 2018-05-15 | |||||||
| 2016-12-31 | $0.00 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |